entertainment -WSS

entertainment

author：entertainment 2025-09-06 10:13:48 - browse：69

Sarepta - Cambridge -AP — A logo sign outside of the headquarters of Sarepta Therapeutics in Cambridge, Mass. Kristoffer Tripplaar/Sipa via AP

Reviewers at the Food and Drug Administration were leaning toward rejecting a closely watched gene therapy for Duchenne muscular dystrophy made by Sarepta Therapeutics, prompting a top official to intervene earlier this year, according to three people with direct knowledge of the agency deliberations.

Inside the FDA office that oversees gene therapies, some staff had reached a non-binding conclusion that Sarepta’s gene therapy should be rejected, the individuals said, speaking on condition of anonymity. Peter Marks, a top FDA official and vocal advocate for faster gene therapy approvals, stepped in and directed staff to schedule a public hearing on the therapy on May 12.

Sarepta announced the scheduling of the public hearing last month, but the internal deliberations that led to it have not been previously reported.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Data don't support strong claims for Covid

WSS

Commercial surrogacy can be ethical, despite pope’s claims

BD to buy Edwards patient monitoring unit for $4.2 billion

For pregnant people, addiction treatment shouldn't mean a call to child protective services

FDA drug safety: Singulair case shows systemic surveillance flaws

Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

FDA approves Moderna’s RSV vaccine, its second licensed product

hotspot

entertainment

hotspot

New air purifier tech could be key to improving indoor air quality

Vertex non

Alkermes shareholders re

New Ultima Genomics DNA sequencer can read genome for $100

Supreme Court strikes down use of affirmative action

Structure Therapeutics oral GLP

Cancer drug shortages should be causing more outrage

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

After affirmative action ruling, medical educators look to 'holistic review'

The real point of Kenneth Smith’s execution by nitrogen gas

hotspot

Cognito secures funding to test medical device for Alzheimer's

FDA approves Moderna’s RSV vaccine, its second licensed product

FDA drug safety: Singulair case shows systemic surveillance flaws

An outdated Medicare rule harms dementia patients with anxiety

A $475,000 price tag for a new cancer drug: crazy or meh?

The real point of Kenneth Smith’s execution by nitrogen gas

Wikipedia

leisure time

knowledge

Wikipedia